Disc Medicine (NASDAQ:IRON) Director Kevin Bitterman Sells 5,203 Shares of Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Kevin Bitterman sold 5,203 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $79.98, for a total value of $416,135.94. Following the transaction, the director owned 13,445 shares in the company, valued at approximately $1,075,331.10. This trade represents a 27.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Bitterman also recently made the following trade(s):

• On Wednesday, September 2nd, Kevin Bitterman sold 49,164 shares of Disc Medicine stock. The shares were sold at an average price of $80.17, for a total value of $3,941,477.88.
• On Tuesday, September 1st, Kevin Bitterman sold 129 shares of Disc Medicine stock. The shares were sold at an average price of $79.95, for a total transaction of $10,313.55.

Disc Medicine Stock Performance

Shares of NASDAQ:IRON opened at $79.37 on Friday. The firm’s 50 day simple moving average is $77.67 and its 200 day simple moving average is $70.32. Disc Medicine, Inc. has a fifty-two week low of $40.00 and a fifty-two week high of $99.50. The company has a market capitalization of $3.05 billion, a price-to-earnings ratio of -12.06 and a beta of 0.97. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, topping the consensus estimate of ($1.71) by $0.17. As a group, sell-side analysts forecast that Disc Medicine, Inc. will post -6.61 earnings per share for the current year.

Disc Medicine News Summary

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Wedbush raised its price target for Disc Medicine from $88 to $100 and maintained an “outperform” rating. The new target implies approximately 26% upside from the referenced $79.37 price, signaling continued analyst confidence in the company’s prospects. Benzinga analyst price target report
• Neutral Sentiment: Disc Medicine announced that management will participate in fireside chats at four upcoming investor conferences. These events could provide updates on the company’s hematology pipeline, but no new clinical or financial information was disclosed in the announcement. Disc Medicine investor conference announcement
• Negative Sentiment: Director Kevin Bitterman sold a combined 54,496 shares of Disc Medicine for approximately $4.37 million across transactions dated September 1–3. The sales reduced his position by roughly 80% overall, which may concern investors about insider conviction. However, the trades were executed under a pre-arranged Rule 10b5-1 plan, meaning they were scheduled in advance and do not necessarily reflect a current change in his outlook. SEC insider trading filing
• Negative Sentiment: Rosen Law Firm announced an investigation into potential securities claims involving allegations that Disc Medicine may have issued materially misleading business information. The announcement increases headline and litigation risk, although it does not establish wrongdoing or guarantee that a lawsuit will be filed. Rosen Law Firm investigation announcement

Institutional Trading of Disc Medicine

A number of institutional investors have recently modified their holdings of the company. NEXTBio Capital Management LP acquired a new stake in Disc Medicine during the fourth quarter worth approximately $3,397,000. DNB Asset Management AS lifted its position in shares of Disc Medicine by 1,425.8% during the 4th quarter. DNB Asset Management AS now owns 84,255 shares of the company’s stock valued at $6,691,000 after acquiring an additional 78,733 shares during the period. Eagle Health Investments LP bought a new stake in shares of Disc Medicine during the 4th quarter valued at $2,152,000. Vanguard Group Inc. grew its holdings in shares of Disc Medicine by 22.1% during the 4th quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company’s stock worth $140,371,000 after purchasing an additional 319,621 shares in the last quarter. Finally, BlackRock Inc. acquired a new stake in shares of Disc Medicine during the 2nd quarter worth $180,502,000. 83.70% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on IRON. HC Wainwright increased their price target on Disc Medicine from $118.00 to $120.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Disc Medicine in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a research report on Friday, July 17th. Wedbush increased their target price on Disc Medicine from $88.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Morgan Stanley restated an “overweight” rating and set a $90.00 target price on shares of Disc Medicine in a report on Monday, August 17th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $107.70.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.